Everything below concerns melanocortin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
A problem that occurs when treatment affects healthy tissues or organs. (NCI) Any undesired actions or effects of a drug or treatment. Negative or adverse effects may include headache, nausea, hair loss, skin irritation, or other physical problems. Experimental drugs must be evaluated for both immediate and long-term side effects (NLM) Significant
Rose first encountered Fred West at a Cheltenham bus stop in early 1969, shortly after Rose had turned 15 and when Fred was aged 27. She was initially repulsed by Fred's unkempt appearance, but quickly became flattered by the attention he continued to lavish on her over the following days as he invariably sat alongside her at the same bus stop. Rose twice refused to go on a date with Fred, but allowed him to accompany her home. Having discovered Rose worked in a nearby bread shop, Fred persuaded an unknown woman to enter the shop and present her with a gift accompanied by the explanation that "a man outside" had asked her to present the gift to Rose. Minutes later, Fred entered the shop and asked Rose to accompany him on a date that evening. She accepted the offer. Shortly thereafter, Rose began a relationship with Fred, becoming a frequent visitor at the caravan park where he lived with the two children from his first marriage to Catherine "Rena" Costello: daughter Anne Marie and stepdaughter Charmaine. Rose became a willing childminder to Fred's daughters, who she noted were neglected and whom she initially treated with care and affection. On several occasions in the early days of their courtship, Rose insisted she and Fred take the girls on excursions to gather wildflowers. Within weeks of her first encounter with Fred, Rose left her job at the bread shop to become a full-time nanny to his children.
== Weaknesses == The assay is limited to using existing restriction sites in the region of interest, and methylation that does not occur in the context of a specific restriction site will not be assayed. Incomplete digestion by restriction enzymes after PCR can confound the analysis: incomplete digestion would suggest lack of DNA methylation (if cutting with a methylation-sensitive enzyme such as HpaII). It is also known that BstUI can cut at unconverted sites, leading to overestimation of methylation levels and so the use of HpaII is often needed. In complex samples, cell-type heterogeneity can confound the analysis since the DNA is not being sequenced, heterogeneity in sequences from different cells in the sample (i.e. different cell populations within a tumor) that have acquired mutations in the interrogated region, such as changing the CG dinucleotide to CA or CT, would result in loss of the restriction site giving rise to an apparently methylated region due to lack of digestion. This would skew the quantification of DNA methylation levels in a given sample.
With the exception of yellow fever vaccine and Ebola vaccines, vaccines for VHFs are generally not available. For someone exposed to CCHF, ribavirin is available as post-exposure prophylaxis (PEP). Ribavirin may also help in exposure to Lassa fever. Any person who is taking care of a patient with any VHF should take multiple precautions against exposure and infection. The precautions include hand hygiene, double gloves, gowns, shoe and leg coverings, and face shields or goggles. Treatment of any VHF should involve careful donning (putting on) and doffing (taking off) procedures for PPE. A Trained Observer, or TO, is used to monitor the donning/doffing process. Lassa, CCHF, Ebola, and Marburg viruses may be particularly prone to nosocomial (hospital-based) spread. Airborne precautions should be utilized including, at a minimum, a fit-tested, HEPA filter-equipped respirator (such as an N95 mask), a battery-powered, air-purifying respirator, or a positive pressure supplied air respirator to be worn by personnel coming within 1.8 metres (six feet) of a VHF patient. Groups of patients should be cohorted (sequestered) to a separate building or a ward with an isolated air-handling system. Environmental decontamination is typically accomplished with hypochlorite (e.g. bleach) or phenolic disinfectants. Some VHF patients, notably those infected with Marburg and Ebola, are at their most infectious after death. Strict precautions should be taken including the safe transport and disinfection of the body.
Sources: en.wikipedia.org
Diversity of this class of material as compared to normal chemical substances makes the assessment of their toxicity very challenging. As their toxicity may also be dynamic depending on the environmental factors such as pH level, light exposure, and cell type, traditional methods of assessing toxicity of chemicals such as LD50 are not applicable for QDs. Therefore, researchers are focusing on introducing novel approaches and adapting existing methods to include this unique class of materials. Furthermore, novel strategies to engineer safer QDs are still under exploration by the scientific community. A recent novelty in the field is the discovery of carbon quantum dots, a new generation of optically active nanoparticles potentially capable of replacing semiconductor QDs, but with the advantage of much lower toxicity.
Frydman RB, Tomaro ML, Frydman B (1972). "Pyrrolooxygenase: its action on tryptophan-containing enzymes and peptides". Biochim. Biophys. Acta. 284 (1): 80–9. doi:10.1016/0005-2744(72)90047-2. PMID 4403729.
== Further reading == Marcus, Raphael D. Israel's Long War with Hezbollah: Military Innovation and Adaptation under Fire (Georgetown UP, 2018) online review Rosenthal, Donna (2003). The Israelis. Free Press. ISBN 978-0-7432-7035-9. Ostfeld, Zehava (1994). Shiftel, Shoshana (ed.). An Army is Born (in Hebrew). Israel Ministry of Defense. ISBN 978-965-05-0695-7. Gelber, Yoav (1986). Nucleus for a Standing Army (in Hebrew). Yad Ben Tzvi. Yehuda Shif, ed. (1982). IDF in Its Corps: Army and Security Encyclopedia (18 volumes) (in Hebrew). Revivim Publishing. Ron Tira, ed. (2009). The Nature of War: Conflicting Paradigms and Israeli Military Effectiveness. Sussex Academic Press. ISBN 978-1-84519-378-2. Roislien, Hanne Eggen (2013). "Religion and Military Conscription: The Case of the Israeli Defense Forces (IDF)," Armed Forces & Society 39, No. 3, pp. 213–232. Country Briefing: Israel, Jane's Defence Weekly, 19 June 1996
== Further reading == Anie KA, Massaglia P (March 2014). "Psychological therapies for thalassaemia". The Cochrane Database of Systematic Reviews. 2014 (3) CD002890. doi:10.1002/14651858.cd002890.pub2. PMC 7138048. PMID 24604627. Galanello R, Cao A (February 2011). "Gene test review. Alpha-thalassemia". Genetics in Medicine. 13 (2): 83–8. doi:10.1097/GIM.0b013e3181fcb468. PMID 21381239. S2CID 209070781.
fatty acid Any of a subclass of lipid compounds consisting of a carboxylic acid bonded to an aliphatic chain of hydrocarbons, usually 4 to 28 carbon atoms in length, which may be either saturated (containing only single bonds between the carbon atoms) or unsaturated (containing one or more double bonds). In biological systems, fatty acid chains are commonly linked to other compounds via ester bonds, primarily in triglycerides, phospholipids, and derivatives of cholesterol, all of which serve a wide variety of important cellular functions including as structural components of membranes and as energy sources in metabolic pathways.
Sources: en.wikipedia.org
Elements of the morphine structure have been used to create completely synthetic drugs such as the morphinan family (levorphanol, dextromethorphan and others) and other groups that have multiple members with morphine-like qualities. The modification of morphine and the aforementioned synthetics has also given rise to non-narcotic drugs with other uses such as emetics, stimulants, antitussives, anticholinergics, muscle relaxants, local anaesthetics, general anaesthetics, and others. Morphine-derived agonist–antagonist drugs have also been developed.
=== Human === In humans (and perhaps in all placental mammals), the most common form is fetomaternal microchimerism (also known as fetal cell microchimerism or fetal chimerism) whereby cells from a fetus pass through the placenta and establish cell lineages within the mother. Fetal cells have been documented to persist and multiply in the mother for several decades. The exact phenotype of these cells is unknown, although several different cell types have been identified, such as various immune lineages, mesenchymal stem cells, and placental-derived cells. A 2012 study at the Fred Hutchinson Cancer Research Center, Seattle, has detected cells with the Y chromosome in multiple areas of the brains of deceased women. Fetomaternal microchimerism occurs during pregnancy and shortly after giving birth for most women. However, not all women who have had children contain fetal cells. Studies suggest that fetomaternal microchimerism could be influenced by killer-cell immunoglobulin-like (KIR) ligands. Lymphocytes also influence the development of persisting fetomaternal microchimerism since natural killer cells compose about 70% of lymphocytes in the first trimester of pregnancy. KIR patterns on maternal natural killer cells of the mother and KIR ligands on the fetal cells could have an effect on fetomaternal microchimerism. In one study, mothers with KIR2DS1 exhibited higher levels of fetomaternal microchimerism compared to mothers who were negative for this activating KIR. The potential health consequences of these cells are unknown.
Copolymers are classified either as statistical copolymers, alternating copolymers, block copolymers, graft copolymers or gradient copolymers. In the schematic figure below, Ⓐ and Ⓑ symbolize the two repeat units.
RSH + GSH + [O] → GSSR + H2O Glutathione is also employed for the detoxification of methylglyoxal and formaldehyde, toxic metabolites produced under oxidative stress. This detoxification reaction is carried out by the glyoxalase system. Glyoxalase I (EC 4.4.1.5) catalyzes the conversion of methylglyoxal and reduced glutathione to S-D-lactoylglutathione. Glyoxalase II (EC 3.1.2.6) catalyzes the hydrolysis of S-D-lactoylglutathione to glutathione and D-lactic acid. It maintains exogenous antioxidants such as vitamins C and E in their reduced (active) states.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.